Anguo Yin

1 Introduction Rabies caused by genotype 1 rabies virus (RABV) is a globally lethal zoonotic disease, predominantly prevalent across Asia and Africa. Insufficient access to timely post-exposure prophylaxis (PEP) greatly elevates mortality; once clinical encephalomyelitis develops after RABV invades the central nervous system, the disease is almost invariably fatal, highlighting an urgent demand for potent prophylactic vaccines [1].